Amgen Bows Out Of Partnership With AstraZeneca On Phase III Brodalumab
This article was originally published in The Pink Sheet Daily
Executive Summary
Company drops deal to co-develop and commercialize the IL-17 blocker in psoriasis, cites reports of suicidal ideation.